1. T1D is reduced in anti-CD3–treated, CXCL10-deficient RIP-LCMV-GP mice (the numbers in parentheses indicate the number of mice in each group).
T1D is reduced in anti-CD3–treated, CXCL10-deficient RIP-LCMV-GP mice (the numbers in parentheses indicate the number of mice in each group). The study of diabetes remission in normal RIP-LCMV-GP and CXCL10-deficient RIP-LCMV-GP mice that were treated with aCD3. For aCD3 therapy, mice were administered three daily injections of 3 µg aCD3 at days 10–12 after LCMV infection. BG concentrations were determined until week 26 after infection. Concentrations >300 mg/dL were considered to be diabetic. T1D remission was defined as a stable reversion of BG to concentrations below 300 mg/dL. Significant differences are indicated (P values).
Stanley Lasch et al. Diabetes 2015;64:
©2015 by American Diabetes Association